The United States has almost half of the global plasma market size.

According to the International Data Corporation, the health care industry generated about 153 exabytes of data in 2013, roughly equivalent to 2.6 trillion music albums. That number will skyrocket to an estimated 2,314 exabytes in 2020, more than an 11,000% spike.

Startup idea? Data management platform.

Synthetic biology market size has grown from $4.2B in 2014 to $9.5B in 2021; it is estimated to reach $30.7B by 2026.

$27 billion invested in longevity startups.

In past biotech companies tended to be founded with a focus on a single technology or biological pathway.

Over the past five years an innovative business model has emerged for biotech. In it, a portfolio manager controls a set of companies spanning multiple technologies and disease areas.

Instead of focusing on a single technology or in the traditional way, the portfolio manager uses a distinctive form of expertise — such as in fundraising, investment, venture creation, R&D, manufacturing, commercial management, leadership, and broad credibility — to start a suite of subsidiaries, each dedicated to an individual drug program.

Global market for gene editing will grow at a compound annual growth rate of 33.26% from $551.2 million in 2017 to $3.087 billion in 2023.

The North American market will account for the largest share of the gene editing market due to “increasing awareness of technology, proximity of companies, and early adoption of latest treatments.”

Asia was expected to be the second-largest market, due to “increasing government funding of research, economic prosperity, early adoption of latest technology and the relaxed”.

The total amount of VC funding in AI-biotech startups increased in 2020 (as of November) by around 23%, compared to 2019, approaching a total of $1.9B, which is also more than in 2015, 2016 and 2017 combined.

An important driver of growth for the sector is a substantial shift in Big Pharma’s interest in AI technology from “nice to try” to “strategically important”.

Demand for blood is steadily growing:

— 81 million blood donations were collected in 2004;
— 108 million were collected in 2015;
— 118.5 million blood donations are collected globally nowadays.

Great opportunity for artificial blood companies?

Nanotechonology market size is estimated at $42.2B in 2020 and is expected to reach $70.7B by 2026

Artificial blood market size — $2.1B in 2019 with a potential to reach $15.4B by 2027.

95% of the market size shares two blood substitutes that carry out functions of transporting oxygen and carbon dioxide:

— The first one is called hemoglobin-based oxygen carrier and has over 53%;
— the second one is perfluorocarbon emulsion and has approximately 42%.

Nanorobotics market size is estimated to grow from $4.9B in 2018 to $8.3B by 2023.

Source: Markets and Markets